Page 52 - 《中国医疗器械杂志》2025年第6期

Chinese Journal of Medical Instrumentation 2025年 第49卷 第6期

综 合 评 述

diseases: a novel biomarker for diagnosis and potential [28] FARRÉ P L, DUCA R B, MASSILLO C, et al. MiR-
therapeutic targets?[J]. Cureus, 2024, 16(7): e64100. 106b-5p: a master regulator of potential biomarkers for
[14] MIR R, ELFAKI I, KHULLAR N, et al. Role of selected breast cancer aggressiveness and prognosis[J]. Int J Mol
miRNAs as diagnostic and prognostic biomarkers in Sci, 2021, 22(20): 11135.
cardiovascular diseases, including coronary artery [29] DE LA CRUZ-OJEDA P, SCHMID T, BOIX L, et al.
disease, myocardial infarction and atherosclerosis[J]. J miR-200c-3p, miR-222-5p, and miR-512-3p constitute a
Cardiovasc Dev Dis, 2021, 8(2): 22. biomarker signature of sorafenib effectiveness in
[15] WANG L, ZHANG L J. Circulating exosomal miRNA as advanced hepatocellular carcinoma[J]. Cells, 2022,
diagnostic biomarkers of neurodegenerative diseases[J]. 11(17): 2673.
Front Mol Neurosci, 2020, 13: 53. [30] CHEN S Y, MAO Y Q, CHEN W, et al. Serum exosomal
[16] PISCOPO P, BELLENGHI M, MANZINI V, et al. A sex miR-34a as a potential biomarker for the diagnosis and
perspective in neurodegenerative diseases: microRNAs as prognostic of hepatocellular carcinoma[J]. J Cancer,
possible peripheral biomarkers[J]. Int J Mol Sci, 2021, 2022, 13(5): 1410-1417.
22(9): 4423. [31] LIN J T, TSAI K W. Circulating miRNAs act as
[17] NGUYEN T P N, KUMAR M, FEDELE E, et al. diagnostic biomarkers for bladder cancer in urine[J]. Int J
MicroRNA alteration, application as biomarkers, and Mol Sci, 2021, 22(8): 4278.
therapeutic approaches in neurodegenerative diseases[J]. [32] YANG L, SUN H F, GUO L Q, et al. MiR-10a-5p: A
Int J Mol Sci, 2022, 23(9): 4718. promising biomarker for early diagnosis and prognosis
[18] GRIECO G E, BESHARAT Z M, LICATA G, et al. evaluation of bladder cancer[J]. Cancer Manag Res, 2021,
Circulating microRNAs as clinically useful biomarkers 13: 7841-7850.
for type 2 diabetes mellitus: miRNomics from bench to [33] ZHANG W Q, CHANG G N, CAO L Y, et al.
bedside[J]. Transl Res, 2022, 247: 137-157. Dysregulation of serum miR-361-5p serves as a
[19] MASOUMI-ARDAKANI Y, EGHBALIAN M, biomarker to predict disease onset and short-term
FALLAH H, et al. Exploring serum miR-33b as a novel prognosis in acute coronary syndrome patients[J]. BMC
diagnostic marker for hypercholesterolemia and obesity: Cardiovasc Disord, 2021, 21(1): 74.
insights from a pilot case-control study[J]. BMC Endocr [34] SU Y, SUN Y X, TANG Y S, et al. Circulating miR-19b-
Disord, 2025, 25(1): 27. 3p as a novel prognostic biomarker for acute heart
[20] KIMURA M, KOTHARI S, GOHIR W, et al. failure[J]. J Am Heart Assoc, 2021, 10(20): e022304.
MicroRNAs in infectious diseases: potential diagnostic [35] ZHANG M, HAN W, XU Y H, et al. Serum miR-128
biomarkers and therapeutic targets[J]. Clin Microbiol serves as a potential diagnostic biomarker for Alzheimer’s
Rev, 2023, 36(4): e0001523. disease[J]. Neuropsychiatr Dis Treat, 2021, 17: 269-275.
[21] VENKATESAN G, WAN AB RAHMAN W S, [36] DONG Z W, GU H J, GUO Q, et al. Profiling of serum
SHAHIDAN W N S, et al. Plasma-derived exosomal exosome miRNA reveals the potential of a MiRNA panel
miRNA as potential biomarker for diagnosis and as diagnostic biomarker for Alzheimer’s disease[J]. Mol
prognosis of vector-borne diseases: a review[J]. Front Neurobiol, 2021, 58(7): 3084-3094.
Microbiol, 2023, 14: 1097173. [37] HE S L, HUANG L, SHAO C, et al. Several miRNAs
[22] JANKOVIC M, NIKOLIC D, NOVAKOVIC I, et al. derived from serum extracellular vesicles are potential
miRNAs as a potential biomarker in the COVID-19 biomarkers for early diagnosis and progression of
infection and complications course, severity, and Parkinson’s disease[J]. Transl Neurodegener, 2021, 10(1):
outcome[J]. Diagnostics(Basel), 2023, 13(6): 1091. 25.
[23] AGRAWAL P, UPADHYAY A, KUMAR A, et al. [38] HE J, XIONG J, HUANG Y Y. miR-29 as diagnostic
microRNA as biomarkers in tuberculosis: a new emerging biomarkers for tuberculosis: a systematic review and
molecular diagnostic solution[J]. Diagn Microbiol Infect Meta-analysis[J]. Front Public Health, 2024, 12: 1384510.
Dis, 2024, 108(1): 116082. [39] ABDUL-MAKSOUD R S, RASHAD N M, ELSAYED
[24] LI W G, LIU S D, CHEN Y Y, et al. Circulating W S H, et al. Circulating miR-181a and miR-223
exosomal microRNAs as biomarkers of systemic lupus expression with the potential value of biomarkers for the
erythematosus[J]. Clinics, 2020, 75: e1528. diagnosis of systemic lupus erythematosus and predicting
[25] PENG X L, WANG Q, LI W M, et al. Comprehensive lupus nephritis[J]. J Gene Med, 2021, 23(5): e3326.
overview of microRNA function in rheumatoid [40] GONG J M, ZHANG X S, KHAN A, et al. Identification
arthritis[J]. Bone Res, 2023, 11(1): 8. of serum exosomal miRNA biomarkers for diagnosis of
[26] SMOLARZ M, WIDLAK P. Serum exosomes and their Rheumatoid arthritis[J]. Int Immunopharmacol, 2024,
miRNA load—a potential biomarker of lung cancer[J]. 129: 111604.
Cancers, 2021, 13(6): 1373. [41] DAVE V P, NGO T A, PERNESTIG A K, et al.
[27] KAN J Y, SHIH S L, YANG S F, et al. Exosomal MicroRNA amplification and detection technologies:
microRNA-92b is a diagnostic biomarker in breast cancer opportunities and challenges for point of care
and targets survival-related MTSS1L to promote diagnostics[J]. Lab Invest, 2019, 99(4): 452-469.
tumorigenesis[J]. Int J Mol Sci, 2024, 25(2): 1295. [42] WANG H Z, YU R M, ZHU Q Q, et al. A highly

638